Calorie restriction (CR) is the most important treatment for weighting loss. In recent years, two novel types of intermittent fasting recently have gained more attention: the 5:2 diet and time-restricted eating (TRE). TRE requires individuals to eat in a specified number of hours per day (typically 4 to 10 hours) without energy intake restriction. The 5:2 diet involves 5 feast days and 2 fast days per week; participants eat ad libitum without restriction on feast days while 25% of energy needs (approximately 500-800 kcal per day) are consumed on fast days. However, the effects of dietary strategy of intermittent fasting plus time-restricted eating (modified time-restricted eating: TRE 5 days and fasting 2days per week) on weight loss and cardiometabolic risk factors in obese adults have not been proved. This randomized controlled trial aimed to evaluate the effect of modified time-restricted eating (mTRE) and CR on weight loss and cardiometabolic risk factors in obese adults compared to usual health care over 12 months.
Obesity is becoming a major global public health issue. Calorie restriction (CR) is the most important treatment for weighting loss. In recent years, two novel types of intermittent fasting recently have gained more attention: the 5:2 diet and time-restricted eating (TRE). TRE requires individuals to eat in a specified number of hours per day (typically 4 to 10 hours) without energy intake restriction. The 5:2 diet involves 5 feast days and 2 fast days per week; participants eat ad libitum without restriction on feast days while 25% of energy needs (approximately 500-800 kcal per day) are consumed on fast days. However, the effects of dietary strategy of intermittent fasting plus time-restricted eating (modified time-restricted eating: TRE 5 days and fasting 2days per week) on weight loss and cardiometabolic risk factors in obese adults have not been proved. This randomized controlled trial aimed to evaluate the effect of modified time-restricted eating (mTRE) and CR on weight loss and cardiometabolic risk factors in obese adults compared to usual health care over 12 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
225
Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.
Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
RECRUITINGChange in body weight over 12 months
Change in body weight over 12 months
Time frame: Baseline to months 12
Change in body mass index (BMI)
body mass index : the weight in kilograms divided by the square of the height in meters.The higher scores mean a worse outcome.
Time frame: Baseline to months 12
Change in waist circumference
Wrap a tape measure around the waist at the level of the navel.
Time frame: Baseline to months 12
Change in body fat composition meassured by DEXA
Body composition is meassured by dual-energy X-ray absorptiometry scans
Time frame: Baseline to months 12
Change in liver fat
Liver fat is assessed by liver Fibroscan
Time frame: Baseline to months 12
Change in systolic blood pressure
blood pressure
Time frame: Baseline to months 12
Change in diastolic blood pressure
blood pressure
Time frame: Baseline to months 12
Change in concentration of serum triglyceride
the contents of serum triglyceride
Time frame: Baseline to months 12
Change in concentration of serum total cholesterol
the contents of serum total cholesterol
Time frame: Baseline to months 12
Change in concentration of serum LDL-c
the contents of Low Density Lipoprotein
Time frame: Baseline to months 12
Change in concentration of HbA1c
the contents of Glycated hemoglobin
Time frame: Baseline to months 12
Change in insulin sensitivity
Insulin sensitivity is assessed by HOMA-IR (Homeostatic Model Assessment for Insulin Resistance).
Time frame: Baseline to months 12
Change in β cell function
β cell function is assessed by HOMA-B
Time frame: Baseline to months 12
Change in arterial stiffness measured by pulse wave velocity
arterial stiffness is measured by pulse wave velocity (PWV)
Time frame: Baseline to months 12
Change in depression score measured by the Patient Health Questionnaire-9
Depression is measured by the Patient Health Questionnaire-9 (PHQ-9). The maximum value is 27, and the minimum value is 0 . The higher scores mean a worse outcome.
Time frame: Baseline to months 12
Change in quality of sleep score measured by the Pittsburgh sleep quality index
Quality of sleep is measured by the Pittsburgh sleep quality index (PSQI). The maximum value is 21, and the minimum value is 0 . The higher scores mean a worse outcome.
Time frame: Baseline to months 12
Change in quality of life score measured by the 12-item Short-Form Health Survey Questionnaire
Quality of life is measured by the 12-item Short-Form Health Survey Questionnaire (SF-12). The maximum value is 100, and the minimum value is 0 . The higher scores mean a better outcome.
Time frame: Baseline to months 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.